The pharmaceutical development pipeline generates a substantial body of clinical evidence across multiple studies, each conducted with its own protocol, patient population, data collection instruments, and analysis approach. The insights available from analysing this evidence in aggregate — patterns not visible in any single study, effects in subgroups too small to power individual studies, benefit-risk signals that span the development programme — are rarely fully realised. The reason is not scientific but infrastructural: the studies were not designed with cross-study compatibility in mind, and the data harmonization required to make them analytically compatible is expensive and time-consuming when approached on a study-by-study basis.
The Single-Study Limitation
Individual clinical studies are designed to answer specific questions about specific populations. They are powered to detect specific effect sizes in those populations, and their formal conclusions are limited to the population and context studied. The broader question of how findings generalise across populations, subgroups, geographies, and treatment settings cannot be answered from any single study. Answering it requires pooling evidence across studies — a technically complex exercise that demands harmonized data structures, compatible outcome definitions, and comparable analytical approaches across all contributing studies. The richer the available evidence base, the greater the lost analytical opportunity when that evidence cannot be combined.
Semantic Harmonization as the Foundation
Cross-study analytics depends on data harmonization: mapping the data collected in each study to a common representational framework. In practice, this means mapping each study's data collection instruments, coded values, and outcome definitions to a shared ontological vocabulary, so that a condition documented in one study's case report form is recognised as the same condition documented using different field names and codes in another study. Ontological harmonization goes further than simple variable mapping. It captures the conceptual relationships between variables — which outcomes are subtypes of broader outcome categories, which adverse events belong to the same system organ class, which patient characteristics express the same underlying clinical dimension. This conceptual structure enables meaningful aggregation based on shared clinical meaning rather than on incidentally shared field values.
Pooled Population and Subgroup Analysis
When study data are harmonized to a shared ontological framework, pooled population analyses become tractable at a scale individual studies cannot achieve. A team investigating treatment effects in a specific patient subgroup — defined by a combination of baseline characteristics, comorbidities, and prior treatment history — can query across all available studies for patients meeting those characteristics, regardless of which study collected them and regardless of the local field names used to document those characteristics. The result is a pooled cohort that may be orders of magnitude larger than any individual study, enabling the detection of effects in subgroups that would have insufficient statistical power in any single study design.
Benefit-Risk Synthesis Across the Development Programme
For regulatory applications, cross-study analytics is directly relevant to benefit-risk synthesis and product label development. Benefit claims in regulatory submissions need to be supported by the totality of evidence across the development programme, not just the pivotal studies. Risk characterisation requires aggregating adverse event data across all available studies to identify signals present at low frequency in any individual study but at meaningful frequency in the pooled dataset. An ontological framework spanning the development programme enables this synthesis systematically, producing benefit-risk documentation that is both more comprehensive and more efficiently generated than what is achievable through manual cross-study review.
Real-World Evidence Integration
The same semantic harmonization framework that enables cross-study analytics within the clinical development programme also provides the foundation for integrating real-world evidence after approval. Post-marketing observational studies, registry data, and electronic health record analyses can be mapped to the same ontological framework as the interventional studies, enabling combined analyses that bridge the controlled trial setting and real-world clinical practice. This integration capability is increasingly relevant as regulatory agencies and health technology assessment bodies place greater weight on real-world evidence in both initial approvals and post-marketing label updates — and organisations that establish semantic harmonization infrastructure during development are positioned to extend it naturally into the post-approval evidence generation that the contemporary regulatory environment demands.
